NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO.,LTD.

Andere talen Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.

Aandelen

603707

CNE100002WP3

slotkoers Shanghai S.E. Andere beurzen 00:00:00 08-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
13,5 ^CNY	-1,39%		-1,46%	-10,00%

01/05	NKFPharma krijgt goedkeuring voor registratie nieuwe kankerbehandeling	MT
27/04	Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Rapporteert winstresultaten voor het eerste kwartaal eindigend op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

NKFPharma Gets Nod to Register New Cancer Treatment	01/05
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	27/04
King-Friend Biochemical Pharmaceutical's Unit Gets US FDA Nod to Market Oxaliplatin Injection	16/01
NKFPharma Gets Certificate to Register Voriconazole for Injection	11/01
Nanjing King-Friend’s Cancer Drug Get US FDA Nod	28/12
King-Friend Biochemical Pharma Gets Certificates for Registration of Micafungin Sodium for Injection	22/12
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27-10-23
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. Announces an Exclusive Licensing Agreement with Tonghua Dongbao Pharmaceutical Co., Ltd. to Commercialize Three Insulin Biosimilars - Insulin Aspart, Insulin Lispro, and Insulin Glargine in the U.S	21-09-23
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	28-08-23
Nanjing King-Friend Wins FDA Nod to Market Generic Version of Aloxi in US	17-08-23
NKFPharma Unit Gets US FDA's Nod for Plerixafor Injection	26-07-23
NKFPharma Unit Gets US FDA Nod for Cancer Drug	21-07-23
NKFPharma Unit Gets FDA Greenlight to Market Anesthetic in the US	27-06-23
NKFPharma Unit Gets FDA Nod for US Registration of Rocuronium Bromide	10-05-23
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	28-04-23
NKFPharma Gets Certification for Lung Cancer Drug	11-04-23
NKFPharma's Nadroparin Calcium Injection Passes Drug Regulator’s Evaluation	21-02-23
Nanjing King-friend Unit’s Anti-Cancer Drug Enters US Market	15-12-22
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	28-10-22
Chimigen Bio announced that it has received CNY 100 million in funding from Zhejiang Puhua Tianqin Equity Investment Management Co., Ltd., Lapam Capital, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd and other investors	22-09-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.

Aandelen

603707

CNE100002WP3

Andere talen

Filters